Figure 6. Ropivacaine attenuates the tumor growth of breast cancer in vivo. (A–F) The effect of ropivacaine on tumor growth of breast cancer cells in vivo was analyzed by nude mice tumorigenicity assay by injected with the MDA-MB-231 cells. The mice (n = 5) were treated with equal volume saline, or ropivacaine (40 μmol/Kg), or co-treated with ropivacaine (40 μmol/Kg) and miR-27b-3p inhibitor. (A) Representative images of dissected tumors from nude mice were presented. (B) The average tumor volume was calculated and shown. (C) The average tumor weight was calculated and shown. (D) The levels of ki-67 and PCNA were measured by immunohistochemistry analysis in the mice. (E) The expression levels of miR-27b-3p were examined by qPCR assays in the tumor tissues of the mice. (F) The expression levels of YAP were measured by qPCR assays in the tumor tissues of the mice. Data are presented as mean ± SD. Statistic significant differences were indicated: ##P < 0.0, **P < 0.01.